Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Glaxo Operations UK Limited, 980 Great West Road,Brentford,TW8 9GS Trading as: GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex UB11 1BT
Zinacef for Injection or Infusion.
| Pharmaceutical Form |
|---|
|
Cefuroxime is a white to cream powder to which appropriate amounts of water are added to prepare an off-white suspension for intramuscular use or a yellowish solution for intravenous administration. |
Vials contain either 250 mg, 750mg or 1.5g cefuroxime (as sodium).
The total quantity of sodium per vial is as follows:
| Zinacef strength | Amount of sodium per vial |
|---|---|
| 250 mg | 14 mg |
| 750 mg | 42 mg |
| 1.5 g | 83 mg |
| Active Ingredient | Description | |
|---|---|---|
| Cefuroxime |
Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death. |
| List of Excipients |
|---|
|
None. |
* Only the 1.5g injection pack is marketed (the infusion pack is not)
Glaxo Operations UK Limited, 980 Great West Road,Brentford,TW8 9GS
Trading as:
GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex UB11 1BT
PL 00004/0263
28 April 2002
| Drug | Countries | |
|---|---|---|
| ZINACEF | Brazil, Cyprus, Estonia, Finland, Hong Kong, Ireland, Israel, Lithuania, Malta, New Zealand, Poland, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
